Fig. 6.

Kaplan–Meier curves of C+T- or T-treated breast cancer patients stratified by poly-ligand profiling or by tumour Her2 status. a Kaplan–Meier curve of C+T- or T-treated breast cancer patients stratified by poly-ligand profiling. The shortest distance between the ROC curves to point (specificity and sensitivity = 100%) determines the cutoff of test positive and negative and is represented as the blue point in Fig. 5c (Sensitivity: 78.6%; Specificity: 73.7%). “Event” is defined as the time point (days) at which a patient either deceased from cancer or at which trastuzumab-based treatment changed. Median time of benefit is 429 days for patients tested positive (blue, n = 37, event = 25) and 129 days for patients tested negative (red, n = 24, event = 20). HR = 0.384, 95% CI: 0.21–0.70; log-rank p = 0.001. The small vertical lines mark cases that were censored due to absence of treatment follow-up data (Supplementary Data 4). b Kaplan–Meier curve of C+T- or T-treated breast cancer patients stratified by tumours’ HER2 status. HER2 status of patients with both HER2 IHC and HER2 ISH test results was determined according to ASCO guidelines³⁶. Median time of benefit is 280 days for HER2 positive cases (blue, n = 39, event = 29), and 336 days for HER2-negative/equivocal cases (red; n = 22, event = 16). HR = 1.27, 95% CI: 0.68–2.37; log-rank p = 0.448